Profile data is unavailable for this security.
About the company
OncoZenge AB is a Sweden-based pharmaceutical company, that develops products for cancer supportive care. OncoZenge's vision is to improve the quality of life for patients with severe oral pain, for example caused by radiotherapy or chemotherapy in the treatment of cancer. The Company works on the introduction of its project BupiZenge. Its strategic and operational work focuses on the development of BupiZenge, which is a formulation of bupivacaine in the form of a lozenge. BupiZenge meets a need for pain relief in the mouth and throat, for example associated with oral mucositis, a serious complication after radiation or other cancer treatment. Preparations for registration establishment clinical studies are ongoing.
- Revenue in SEK (TTM)0.00
- Net income in SEK-11.78m
- Incorporated2020
- Employees--
- LocationOncozenge ABGustavslundsvagen 34BROMMA 167 51SwedenSWE
- Phone+46 8311420
- Websitehttps://oncozenge.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lipigon Pharmaceuticals AB | 9.33m | -20.25m | 24.03m | -- | -- | 0.9519 | -- | 2.58 | -0.3541 | -0.3541 | 0.1012 | 0.1702 | 0.2851 | -- | 0.7439 | -- | -61.91 | -314.67 | -76.67 | -426.49 | -- | -- | -217.15 | -488.14 | -- | -- | 0.00 | -- | -- | 444.44 | 67.83 | -- | -- | -- |
| Ziccum AB | 5.56m | -23.18m | 37.82m | 10.00 | -- | 4.46 | -- | 6.81 | -1.63 | -1.63 | 0.3903 | 0.5312 | 0.2749 | -- | 3.31 | 694,500.00 | -114.67 | -68.51 | -163.12 | -76.47 | -- | -- | -417.19 | -2,598.03 | -- | -- | 0.0654 | -- | -- | 75.20 | 25.62 | -- | -13.45 | -- |
| StenoCare A/S | 4.90m | -26.36m | 40.90m | 9.00 | -- | 1.27 | -- | 8.34 | -1.04 | -1.04 | 0.1868 | 1.01 | 0.0948 | -- | 2.07 | -- | -50.98 | -28.16 | -68.69 | -35.47 | -- | -- | -537.63 | -371.06 | 0.6143 | -6.07 | 0.2763 | -- | -16.30 | -- | -7.77 | -- | -- | -- |
| QUIA PHARMA AB (publ) | 2.36m | -13.86m | 41.72m | 8.00 | -- | 1.20 | -- | 17.68 | -2.02 | -2.02 | 0.0119 | 0.0233 | 0.0703 | -- | 21.36 | -- | -41.30 | -95.67 | -50.35 | -207.86 | 160.51 | 262.59 | -587.29 | -5,002.50 | -- | -46.79 | 0.00 | -- | -- | -- | 17.75 | -- | 47.06 | -- |
| Odi Pharma AB (publ) | 22.45m | 355.97k | 48.10m | -- | 135.10 | 21.69 | 134.00 | 2.14 | 0.0234 | 0.0234 | 1.47 | 0.1457 | 2.19 | 54.42 | 5.47 | -- | 3.48 | -35.08 | 14.86 | -44.27 | 2.07 | -- | 1.59 | -99.25 | 1.22 | 1.81 | -- | -- | 15,995.75 | -- | 105.16 | -- | -- | -- |
| Arctic Bioscience AS | 30.69m | -47.25m | 51.55m | 20.00 | -- | 0.2245 | -- | 1.68 | -1.91 | -1.91 | 1.24 | 9.27 | 0.1057 | 0.674 | 2.25 | 1,570,792.00 | -16.27 | -- | -18.44 | -- | 29.20 | -- | -153.95 | -- | 1.21 | -- | 0.0075 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
| ExpreS2ion Biotech Holding AB | 8.10m | -45.37m | 56.71m | 18.00 | -- | 0.629 | -- | 7.00 | -29.54 | -29.54 | 5.47 | 42.93 | 0.0772 | -- | 6.46 | 311,461.50 | -43.23 | -63.54 | -56.21 | -75.88 | -123.56 | -1.94 | -560.27 | -524.31 | -- | -- | 0.0065 | -- | 43.07 | -0.1561 | 22.94 | -- | 19.90 | -- |
| Elicera Therapeutics AB | 12.07m | -20.79m | 69.31m | 2.00 | -- | 2.68 | -- | 5.74 | -0.9137 | -0.9137 | 0.5059 | 0.7377 | 0.3224 | -- | 12.85 | 6,035,610.00 | -55.51 | -40.06 | -79.82 | -49.74 | -- | -- | -172.21 | -415.41 | -- | -- | 0.00 | -- | 777.23 | -- | 15.64 | -- | -- | -- |
| Oncozenge AB | 0.00 | -11.78m | 107.88m | -- | -- | 7.59 | -- | -- | -1.01 | -1.01 | 0.00 | 1.21 | 0.00 | -- | -- | -- | -55.08 | -- | -59.44 | -- | -- | -- | -- | -- | -- | -2,944.50 | 0.00 | -- | -- | -- | 65.91 | -- | -- | -- |
| Lipidor AB | 87.00k | -13.53m | 113.88m | -- | -- | 6.77 | -- | 1,308.93 | -0.1505 | -0.1505 | 0.0009 | 0.0207 | 0.005 | -- | 0.1843 | -- | -77.12 | -59.41 | -178.11 | -75.10 | -- | -- | -15,550.58 | -643.36 | -- | -- | 0.00 | -- | 73.33 | -20.33 | 72.24 | -- | -- | -- |
| Pila Pharma AB | 1.03m | -6.92m | 130.21m | 0.00 | -- | 44.35 | -- | 125.92 | -0.3165 | -0.3165 | 0.049 | 0.1082 | 0.2602 | -- | 8.21 | 1,034,020.00 | -174.06 | -108.88 | -276.40 | -121.45 | -406.94 | -42.67 | -668.94 | -1,577.64 | -- | -163.35 | 0.00 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
| Vivesto AB | 0.00 | -98.92m | 138.55m | 4.00 | -- | 0.7737 | -- | -- | -0.1839 | -0.1839 | 0.00 | 0.3328 | 0.00 | -- | -- | 0.00 | -39.70 | -- | -43.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | 64.80 | -- | -- | -- |
Data as of Nov 06 2024. Currency figures normalised to Oncozenge AB's reporting currency: Swedish Krona SEK
0.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 30 Sep 2024 | 3.24k | 0.03% |
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
